- Release Date: 08/09/22 08:34
- Summary: Phase 1 Clinical Trial Summary
- Price Sensitive: No
- Download Document 202.58KB
- Forums
- ASX - By Stock
- AGN
- Ann: Phase 1 Clinical Trial Summary
Ann: Phase 1 Clinical Trial Summary
Featured News
Add AGN (ASX) to my watchlist
(20min delay)
|
|||||
Last
78.0¢ |
Change
0.005(0.65%) |
Mkt cap ! $99.91M |
Open | High | Low | Value | Volume |
77.5¢ | 80.0¢ | 77.0¢ | $140.6K | 179.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 8842 | 77.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
78.5¢ | 1992 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 8842 | 0.770 |
2 | 11478 | 0.765 |
2 | 13128 | 0.760 |
2 | 13755 | 0.755 |
4 | 24183 | 0.750 |
Price($) | Vol. | No. |
---|---|---|
0.785 | 1992 | 2 |
0.790 | 3135 | 1 |
0.795 | 12595 | 1 |
0.800 | 46089 | 1 |
0.805 | 1104 | 1 |
Last trade - 13.59pm 12/11/2024 (20 minute delay) ? |
Featured News
AGN (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online